Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
Yuemei Hu(Jiangsu Provincial Center for Disease Control and Prevention), Ningshao Xia(Xiamen University), Yue Huang(Zhengzhou University), Xingcheng Huang(Xiamen University), Xiaowen Hu(Xiamen University), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Feng-Zhu Zheng, Changlin Yang, Ya-Hui Wang-Jiang(Xiamen University), Qiu-Fen Zhang, Xia Zang, Kongxin Zhu(Xiamen University), Weijin Huang(National Institutes for Food and Drug Control), Jiali Quan(Xiamen University), Li Zhang(Fourth Hospital of Changsha), Jun Zhang(Army Medical University), Yafei Li(Army Medical University), Kai Chu(Jiangsu Provincial Center for Disease Control and Prevention), Yingying Su(Xiamen University), Donglin Liu, Shoujie Huang(Xiamen University), Zhaofeng Bi(Xiamen University), Qi Chen(Wayne State University), Han-Min Jiang, Ting Wu(Xiamen University), Ya Zheng(Xiamen University), Guang Sun(Memorial University of Newfoundland)
Cited by 26
Related Papers
Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci
|The American Journal of Human Genetics|2012|269
Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant
|Emerging infectious diseases|2018|268
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress
|Human Molecular Genetics|2004|247
Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
|Clinical Rheumatology|2010|230